Dupont Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Dupont Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-36,202	Closed	-$310K	–	1010
2018 Q1	$310K	Hold	36,202	–	–	0.01%	756
2017 Q4	$358K	Hold	36,202	–	–	0.01%	728
2017 Q3	$445K	Hold	36,202	–	–	0.01%	701
2017 Q2	$596K	Hold	36,202	–	–	0.01%	641
2017 Q1	$519K	Buy	+36,202	New	+$537K	0.01%	687

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SGA

Sector Gamma AS Oslo, Norway $423M AUM 17.56% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Dupont Capital Management's LXRX Position: Q2 2018 in Review

Dupont Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2018, closing a stake of 36,202 shares — an estimated $310K sold.

Dupont Capital Management first reported a position in LXRX in Q1 2017 and held it in 5 quarters. The position peaked at $596K in Q2 2017. 121 funds tracked by Wall St. Rank hold LXRX as of Q2 2018.

Dupont Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Dupont Capital Management sold 36,202 Lexicon Pharmaceuticals shares in Q2 2018, an estimated $310K.
Dupont Capital Management first reported a position in Lexicon Pharmaceuticals in Q1 2017 and held it in 5 quarters.
Dupont Capital Management's Lexicon Pharmaceuticals position peaked at $596K in Q2 2017.
121 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2018.

Based on Dupont Capital Management's 13F filing for Q2 2018, filed 30 Jul 2018.